oral RET kinase inhibitor

effective in tumor xenograft model

from scaffold hopping & optimization

ACS Medicinal Chemistry Letters

Novartis Genomics Institute

Chemical structure of molecule compound 1 Novartis RET inhibitor

14.  The Novartis RET inhibitor, compound 1, demonstrated robust oral in vivo efficacy in RET-driven tumor xenografts at low doses (10 mpk QD). RET inhibitors (selpercatinib and pralsetinib) have recently been approved…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: